Alkermes plc (ALKS)
| Market Cap | 5.02B |
| Revenue (ttm) | 1.48B |
| Net Income (ttm) | 241.66M |
| Shares Out | 166.65M |
| EPS (ttm) | 1.43 |
| PE Ratio | 21.05 |
| Forward PE | 17.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,489,334 |
| Open | 30.35 |
| Previous Close | 30.73 |
| Day's Range | 29.91 - 30.49 |
| 52-Week Range | 25.17 - 36.32 |
| Beta | 0.46 |
| Analysts | Buy |
| Price Target | 43.43 (+44.29%) |
| Earnings Date | Feb 25, 2026 |
About ALKS
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramu... [Read more]
Financial Performance
In 2025, Alkermes's revenue was $1.48 billion, a decrease of -5.25% compared to the previous year's $1.56 billion. Earnings were $241.66 million, a decrease of -34.16%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price target is $43.43, which is an increase of 44.29% from the latest price.
News
Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript
Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fo...
Alkermes plc Announces CEO Succession Plan
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) (Alkermes) today announced that Richard Pops will retire from his role as Chief Executive Officer (CEO), effective July 31, 2026. Alkermes' Board o...
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at ...
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) (“Alkermes”) and Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel”) today announced Alkermes' completion of its acquisition of Avadel, a commerci...
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company's fourth qu...
Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Alkermes: Avadel Deal And Vibrance-2 Unlock Upside
Alkermes is transforming into a fully integrated biopharma, leveraging Vibrance-2 results and the Avadel acquisition for competitive advantage in sleep medicine. ALKS's robust legacy portfolio funds r...
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of n...
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthc...
Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL
NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Alkermes to Participate in Two Upcoming Investor Conferences
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 8th Annual Evercore Healthcare Conference Date/Time: Wednesd...
Alkermes raises offer for Avadel after Lundbeck bid
Alkermes said on Wednesday it has sweetened its offer to buy Avadel Pharmaceuticals , beating a rival bid from Denmark's Lundbeck and valuing the sleep disorder drugmaker at up to $2.37 billion.
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIO...
Alkermes plc (ALKS) Shareholder/Analyst Call Transcript
Alkermes plc ( ALKS) Shareholder/Analyst Call November 12, 2025 8:30 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chai...
Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal
Avadel Pharmaceuticals plc (NASDAQ: AVDL) on Friday received an unsolicited proposal from H. Lundbeck A/S for up to $23.00 per ordinary share.
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
Alkermes reviewing options after Lundbeck makes unsolicited bid for Avadel
Alkermes said on Friday it is reviewing its options with advisers after Avadel Pharmaceuticals disclosed it had received an unsolicited takeover proposal from Danish pharmaceutical company Lundbeck.
Alkermes Response to Avadel Announcement
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULAT...
Avadel Receives Unsolicited Proposal from Lundbeck
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FR...
Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study
Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in narcolepsy type 2 (NT2).
Alkermes' narcolepsy drug meets main goal in a mid-stage trial
Alkermes said on Wednesday its experimental narcolepsy drug met the main goals in a mid-stage study.
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the...
FORM 8.1(a) & (b) (Opening Position Disclosure)
DUBLIN , Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS): IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 202...